Graham Kelly

Graham Kelly - Noxopharm Group CEO

BSc (Vet) (Hons, BVSc (Hons), PhD

Graham graduated with degrees in Science (1968) and Veterinary Science (1969) from The University of Sydney. After graduation he joined the newly-formed Department of Transplant Surgery in the Faculty of Medicine at The University of Sydney, gaining a Doctor of Philosophy (Medicine) in 1972. The subject of his PhD thesis was the manufacture and use of a novel drug for the treatment of tissue rejection in kidney transplant recipients, with that drug subsequently being commercialised and used globally in kidney transplantation. Graham was appointed Senior Research Fellow in Experimental Surgery at The University of Sydney, conducting active research in the areas of patient monitoring for tissue rejection and organ retrieval for transplantation. By the mid-1980s, the increased susceptibility of organ transplant recipients to malignant cancer eventually led Graham to focus on the cancer-causing mechanisms operating in organ transplant recipients.

In the early-1990s, Graham identified the compound idronoxil as a promising anti-cancer drug. Graham left academia and founded the company, Norvet Ltd, which listed on the ASX in 1994. That company subsequently changed its name to Novogen Ltd and listed on NASDAQ (1998). Graham was variously CEO, Executive Chairman and an Executive Director of Novogen, 1994-2006. He also was Executive Chairman of Marshall Edwards Inc (MEI) which listed on London's AIM exchange (2001) and NASDAQ (2003). MEI subsequently became MEI Pharma Inc. Graham resigned from his executive and Board positions at Novogen and MEI in 2006.

In 2012, Graham established a private biotechnology company, Macmaster Healthcare, which focused on developing a delivery technology to preserve the activity of idronoxil in the body. That technology eventually became known as the LIPROSE drug delivery technology.

Graham rejoined Novogen in late-2012, remaining as CEO and Executive Chairman until June 2015. In that time, he was responsible for the concepts and development of the drug candidates, Cantrixil and Trilexium, and the creation of a joint venture company with Yale University. After leaving Novogen in 2015, Graham transformed Macmaster Healthcare and the LIPROSE technology platform into Noxopharm Limited, which listed on the Australian Securities Exchange in August 2016.

Graham currently is Group CEO of Noxopharm Ltd, Asian subsidiary, Noxopharm Asia Pty Ltd, and US subsidiary, Nyrada Inc.

James Bonnar

James Bonnar  - Nyrada CEO

BSc (Chemistry), MRQA

James joined Nyrada, Inc. in February 2018 and brings over 20 years of global experience in the Life Sciences industry, including pre-clinical research, operations management, CMC (Chemistry, Manufacturing and Controls), Regulatory Affairs, and Quality Assurance. Before joining Nyrada, James was at Neuren for eleven years. During this period, he was the Director, CMC and Regulatory Affairs and then Director, Clinical Operations where he oversaw clinical development for drugs in the areas of traumatic brain injury and neurodevelopmental disorders. Prior to that he worked in diabetes research, GMP manufacturing, and drug formulation development.

James brings an experienced scientific focus to Nyrada, having led teams from early stage development through to end of Phase II.

Graham Kelly

Mark Waring - Senior Vice President US Operations


Mark is an executive level project manager/researcher/consultant with a proven track record of designing and effecting positive change in international life science companies. Mark graduated from the University of Sydney in Science (Hons) majoring in Pharmacology and Biochemistry in 1986. He also holds certifications as a Project Management Professional (PMP) from PMI and from the American Society of Quality in Pharmaceutical GMP. He has over 30 yrs experience in Research and Development of Pharmaceutical products and Medical Devices. His early career was spent at the University of Sydney and Royal Prince Alfred Hospital (RPAH) Liver Transplant Unit where he lead a team that developed the first Australian Bio-artificial Liver, trialed in humans with liver failure. As part of his work there he also worked with Dr Kelly to describe many new biologically active isoflavones derived from dietary sources.

He joined Novogen Ltd in 1995 and became an early employee of their US subsidiary in 1998, when he moved there with his wife and family to head Clinical Research and Technical affairs in North America. Mark has held roles of increasing responsibility since, including as a project leader for Deloitte Consulting and Quintiles IMS, advising both large and small clients in medical and clinical research, product approval and launch, professional relationship management, safety surveillance, selection and management of strategic partners and GxP compliant systems.

Graham Kelly

Dr. Benny Evison - Chief Scientific Officer

B. Sc. (Med. Sci.) (Hons); PhD

Dr. Benny Evison completed his B. Sc. (Med. Sci.) (Hons) in 2001 and commenced his PhD studies in 2002 at La Trobe University (LTU), Melbourne, Australia. During his PhD at LTU (2002–2007), he gained extensive research experience in the design, development, and analysis of novel DNA-directed therapeutic agents for the treatment of cancer, particularly breast and prostate cancers and lymphomas.

Dr. Evison was appointed as a postdoctoral research fellow in the School of Molecular Sciences, LTU in 2008 where he continued his research in the development of improved anticancer drugs and mentored students at both Honours and PhD levels. He subsequently moved to world-renowned St. Jude Children’s Research Hospital, Memphis, TN, USA, to commence a second postdoctoral research fellowship (2011-2017) where he was involved in the discovery and development of novel inhibitors of DNA repair for the chemosensitisation of paediatric cancers to existing DNA damage based therapies.

In 2017, Dr. Evison returned home to Australia to begin his current post at Nyrada Inc. where he hopes to leverage his extensive scientific experience to generate novel therapeutic entities for the treatment of human diseases.

  Subscribe to Email Alerts